Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases.
作者信息
Dalal Rahul S, Pruce Jordan C, Allegretti Jessica R
机构信息
Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
出版信息
Inflamm Bowel Dis. 2023 May 2;29(5):830-833. doi: 10.1093/ibd/izac164.
Abstract
摘要
相似文献
1
Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases.乌司奴单抗剂量强化治疗炎症性肠病后的长期结局
Inflamm Bowel Dis. 2023 May 2;29(5):830-833. doi: 10.1093/ibd/izac164.
2
Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study.在溃疡性结肠炎中乌司奴单抗剂量强化的预测因素和结果：一项多中心队列研究。
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2399-2401.e4. doi: 10.1016/j.cgh.2021.03.028. Epub 2021 Mar 26.
3
Long-term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center.在东南亚炎症性肠病中心，乌司奴单抗剂量强化的长期疗效和持续率。
J Gastroenterol Hepatol. 2024 Aug;39(8):1544-1553. doi: 10.1111/jgh.16562. Epub 2024 Apr 28.
4
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.乌司奴单抗药代动力学和在溃疡性结肠炎 3 期随机试验中的暴露反应。
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2244-2255.e9. doi: 10.1016/j.cgh.2019.11.059. Epub 2019 Dec 7.
5
Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease.系统评价和荟萃分析：血清乌司奴单抗浓度与炎症性肠病治疗反应的关系。
Inflamm Bowel Dis. 2024 Apr 3;30(4):660-670. doi: 10.1093/ibd/izad065.
6
Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review.乌司奴单抗治疗儿童炎症性肠病的有效性和安全性：系统评价。
Paediatr Drugs. 2023 Sep;25(5):499-513. doi: 10.1007/s40272-023-00586-7. Epub 2023 Aug 1.
7
Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases.系统评价与荟萃分析：炎症性肠病中乌司奴单抗反应丧失及剂量递增需求
Aliment Pharmacol Ther. 2022 Apr;55(7):764-777. doi: 10.1111/apt.16802. Epub 2022 Feb 9.
8
Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification.英夫利昔单抗强化治疗克罗恩病失败的预测因素。
Inflamm Bowel Dis. 2021 Jul 27;27(8):1294-1301. doi: 10.1093/ibd/izaa282.
9
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.英夫利昔单抗剂量升级对标准剂量皮下维持治疗应答不足的克罗恩病患者的疗效。
Aliment Pharmacol Ther. 2020 Jul;52(1):135-142. doi: 10.1111/apt.15784. Epub 2020 May 15.
10
Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.优特克单抗治疗炎症性肠病的有效性和安全性：一项系统评价与Meta分析
Dig Dis Sci. 2022 Mar;67(3):1018-1035. doi: 10.1007/s10620-021-06932-4. Epub 2021 Mar 16.
引用本文的文献
1
Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn's disease who no longer respond to the drug when administered subcutaneously.对于皮下注射优特克单抗不再有反应的克罗恩病患者，每月静脉注射维持治疗可恢复临床反应。
Therap Adv Gastroenterol. 2025 Jul 28;18:17562848251358147. doi: 10.1177/17562848251358147. eCollection 2025.
2
Long-term efficacy of therapeutic drug monitoring-guided optimization of ustekinumab maintenance therapy for Crohn's disease patients.治疗药物监测指导下优特克单抗维持治疗对克罗恩病患者的长期疗效
Sci Rep. 2025 Jul 15;15(1):25540. doi: 10.1038/s41598-025-09802-5.
3
Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations.用于炎症性肠病的白细胞介素-23抑制剂：关键试验与实际考量
Curr Gastroenterol Rep. 2025 Jun 4;27(1):35. doi: 10.1007/s11894-025-00987-3.
4
Persistence and Efficacy of Ustekinumab in Crohn's Disease After Anti-TNF Failure: An Observational Study.优特克单抗在抗TNF治疗失败后对克罗恩病的持续疗效及有效性：一项观察性研究
Dig Dis Sci. 2025 Mar 19. doi: 10.1007/s10620-025-08978-0.
5
Long-Term Effectiveness and Safety of Ustekinumab Dose Escalation in Patients with Moderate-to-Severe Ulcerative Colitis: A Multicenter Retrospective Cohort Study.乌司奴单抗剂量递增疗法用于中重度溃疡性结肠炎患者的长期有效性及安全性：一项多中心回顾性队列研究
Dig Dis Sci. 2025 Mar 17. doi: 10.1007/s10620-025-08977-1.
6
Efficacy of Dose Escalation of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.优特克单抗剂量递增在炎症性肠病中的疗效：一项系统评价和荟萃分析
Med Princ Pract. 2025;34(3):226-237. doi: 10.1159/000543831. Epub 2025 Feb 3.
7
Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study.与抗TNF药物相比，优特克单抗在接受维多珠单抗治疗的炎症性肠病患者中具有更高的持久性：一项真实世界队列研究。
BMC Gastroenterol. 2024 Dec 31;24(1):483. doi: 10.1186/s12876-024-03577-1.
8
IBD Patients with Primary or Secondary Nonresponse to Ustekinumab Benefit from Dose Escalation or Reinduction.对乌司奴单抗原发性或继发性无反应的炎症性肠病患者可从剂量递增或再诱导中获益。
J Clin Med. 2024 Jul 9;13(14):3993. doi: 10.3390/jcm13143993.
9
Approach to loss of response to advanced therapies in inflammatory bowel disease.炎症性肠病对高级治疗反应丧失的处理方法。
World J Gastroenterol. 2024 Jun 14;30(22):2902-2919. doi: 10.3748/wjg.v30.i22.2902.
10
Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States.美国接受优特克单抗治疗的溃疡性结肠炎患者维持期的持续用药情况、剂量递增情况及非生物制剂的使用情况
Crohns Colitis 360. 2023 Sep 4;5(3):otad045. doi: 10.1093/crocol/otad045. eCollection 2023 Jul.
本文引用的文献
1
Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease.治疗药物监测在术后克罗恩病中对肿瘤坏死因子拮抗剂和优特克单抗的应用价值
Inflamm Bowel Dis. 2022 Dec 1;28(12):1865-1871. doi: 10.1093/ibd/izac030.
2
Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases.系统评价与荟萃分析：炎症性肠病中乌司奴单抗反应丧失及剂量递增需求
Aliment Pharmacol Ther. 2022 Apr;55(7):764-777. doi: 10.1111/apt.16802. Epub 2022 Feb 9.
3
Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis.英夫利昔单抗诱导缓解和/或剂量递增治疗克罗恩病的疗效：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2022 Dec;20(12):2728-2740.e1. doi: 10.1016/j.cgh.2021.10.002. Epub 2021 Oct 8.
4
Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study.在溃疡性结肠炎中乌司奴单抗剂量强化的预测因素和结果：一项多中心队列研究。
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2399-2401.e4. doi: 10.1016/j.cgh.2021.03.028. Epub 2021 Mar 26.
5
Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study.每四周90毫克乌司奴单抗强化治疗克罗恩病的有效性和安全性：一项多中心研究。
J Crohns Colitis. 2020 Sep 8. doi: 10.1093/ecco-jcc/jjaa177.
6
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.英夫利昔单抗剂量升级对标准剂量皮下维持治疗应答不足的克罗恩病患者的疗效。
Aliment Pharmacol Ther. 2020 Jul;52(1):135-142. doi: 10.1111/apt.15784. Epub 2020 May 15.
7
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.乌司奴单抗治疗克罗恩病患者的药代动力学和暴露-反应关系。
Gastroenterology. 2018 May;154(6):1660-1671. doi: 10.1053/j.gastro.2018.01.043. Epub 2018 Feb 1.
Zotero 插件